| 創建日期 | 上櫃日期 | 董事長 | 總經理 |
|---|---|---|---|
| 90/02/01 | 101/12/18 | 張東玄 | 楊玫君 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| 0.04(Q2) | 0 | 2.13 | 0% |
| 實收資本額 | 已發行普通股 | ||
| 1,086,401,330 | 108,640,133 | ||
| 主要經營業務 | |||
| 抗癌用之單株抗體開發單株抗體標的授權醣質抗原與蛋白質藥物相關委託服務 | |||
| 公司網址 | |||
| glyconex.com.tw/ | |||
醣聯(4168) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 76 | 28 | 0% | 171.4% | 1,687 | 28,435 | -94.1% |
| 2023/07 | 0 | 45 | -100% | -100% | 1,611 | 28,407 | -94.3% |
| 2023/06 | 521 | 4,640 | -41.2% | -88.8% | 1,611 | 28,362 | -94.3% |
| 2023/05 | 886 | 561 | 0% | 57.9% | 1,090 | 23,722 | -95.4% |
| 2023/04 | 0 | 9,781 | -100% | -100% | 204 | 23,161 | -99.1% |
| 2023/03 | 2 | 13,380 | 0% | -100% | 204 | 13,380 | -98.5% |
| 2023/02 | 0 | 0 | -100% | 0% | 202 | 0 | 0% |
| 2023/01 | 202 | 0 | 339.1% | 0% | 202 | 0 | 0% |
| 2022/12 | 46 | 2,837 | 0% | -98.4% | 30,086 | 5,475 | 449.5% |
| 2022/11 | 0 | 786 | -100% | -100% | 30,040 | 2,638 | 1038.7% |
| 2022/10 | 1,605 | 868 | 0% | 84.9% | 30,040 | 1,852 | 1522% |
| 2022/09 | 0 | 52 | -100% | -100% | 28,435 | 984 | 2789.7% |
| 2022/08 | 28 | 21 | -37.8% | 33.3% | 28,435 | 932 | 2951% |
| 2022/07 | 45 | 58 | -99% | -22.4% | 28,407 | 911 | 3018.2% |
| 2022/06 | 4,640 | 79 | 727.1% | 5773.4% | 28,362 | 853 | 3225% |
| 2022/05 | 561 | 257 | -94.3% | 118.3% | 23,722 | 774 | 2964.9% |
| 2022/04 | 9,781 | 0 | -26.9% | 0% | 23,161 | 517 | 4379.9% |
| 2022/03 | 13,380 | 517 | 0% | 2488% | 13,380 | 517 | 2488% |
| 2022/02 | 0 | 0 | 0% | 0% | 0 | 0 | 0% |
| 2022/01 | 0 | 0 | -100% | 0% | 0 | 0 | 0% |
| 2021/12 | 2,837 | 49 | 260.9% | 5689.8% | 5,475 | 451 | 1114% |
| 2021/11 | 786 | 15 | -9.4% | 5140% | 2,638 | 402 | 556.2% |
| 2021/10 | 868 | 91 | 1569.2% | 853.8% | 1,852 | 387 | 378.5% |
| 2021/09 | 52 | 0 | 147.6% | 0% | 984 | 296 | 232.4% |
| 2021/08 | 21 | 52 | -63.8% | -59.6% | 932 | 296 | 214.9% |
| 2021/07 | 58 | 85 | -26.6% | -31.8% | 911 | 244 | 273.4% |
| 2021/06 | 79 | 16 | -69.3% | 393.8% | 853 | 159 | 436.5% |
| 2021/05 | 257 | 26 | 0% | 888.5% | 774 | 143 | 441.3% |
| 2021/04 | 0 | 20 | -100% | -100% | 517 | 117 | 341.9% |
| 2021/03 | 517 | 0 | 0% | 0% | 517 | 97 | 433% |
| 2021/02 | 0 | 4 | 0% | -100% | 0 | 97 | -100% |
| 2021/01 | 0 | 93 | -100% | -100% | 0 | 93 | -100% |
| 2020/12 | 49 | 70 | 226.7% | -30% | 451 | 734 | -38.5% |
| 2020/11 | 15 | 18 | -83.5% | -16.7% | 402 | 664 | -39.5% |
| 2020/10 | 91 | 156 | 0% | -41.7% | 387 | 646 | -40.1% |
| 2020/09 | 0 | 0 | -100% | 0% | 296 | 490 | -39.6% |
評論0